Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 4
1968 4
1969 6
1970 9
1971 6
1972 4
1973 11
1974 9
1975 10
1976 12
1977 12
1978 13
1979 16
1980 14
1981 14
1982 40
1983 29
1984 25
1985 26
1986 25
1987 18
1988 26
1989 19
1990 17
1991 17
1992 22
1993 19
1994 21
1995 21
1996 25
1997 22
1998 20
1999 20
2000 28
2001 32
2002 29
2003 33
2004 27
2005 29
2006 27
2007 27
2008 36
2009 34
2010 35
2011 30
2012 42
2013 54
2014 36
2015 40
2016 37
2017 36
2018 47
2019 45
2020 42
2021 56
2022 50
2023 41
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

1,334 results

Results by year

Filters applied: . Clear all
Page 1
European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.
Roessner V, Eichele H, Stern JS, Skov L, Rizzo R, Debes NM, Nagy P, Cavanna AE, Termine C, Ganos C, Münchau A, Szejko N, Cath D, Müller-Vahl KR, Verdellen C, Hartmann A, Rothenberger A, Hoekstra PJ, Plessen KJ. Roessner V, et al. Eur Child Adolesc Psychiatry. 2022 Mar;31(3):425-441. doi: 10.1007/s00787-021-01899-z. Epub 2021 Nov 10. Eur Child Adolesc Psychiatry. 2022. PMID: 34757514 Free PMC article. Review.
In 2011, the European Society for the Study of Tourette Syndrome (ESSTS) published the first European guidelines for Tourette Syndrome (TS). We now present an update of the part on pharmacological treatment, based on a review of new literature with spe …
In 2011, the European Society for the Study of Tourette Syndrome (ESSTS) published the first European guidelines for Touret …
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Whiting PF, et al. JAMA. 2015 Jun 23-30;313(24):2456-73. doi: 10.1001/jama.2015.6358. JAMA. 2015. PMID: 26103030 Review.
DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to m …
DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids …
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments.
Billnitzer A, Jankovic J. Billnitzer A, et al. Neurotherapeutics. 2020 Oct;17(4):1681-1693. doi: 10.1007/s13311-020-00914-6. Neurotherapeutics. 2020. PMID: 32856174 Free PMC article. Review.
Tourette syndrome is a heterogeneous neurobehavioral disorder manifested by childhood-onset motor and phonic tics, often accompanied by a variety of behavioral comorbidities, including attention deficit and obsessive compulsive disorder. ...Much more research is nee …
Tourette syndrome is a heterogeneous neurobehavioral disorder manifested by childhood-onset motor and phonic tics, often accom …
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Black N, et al. Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28. Lancet Psychiatry. 2019. PMID: 31672337 Free PMC article.
We also searched for unpublished or ongoing studies on ClinicalTrials.gov, the EU Clinical Trials Register, and the Australian and New Zealand Clinical Trials Registry. ...This study is registered with PROSPERO (CRD42017059372, CRD42017059373, CRD42017059376, CRD420 …
We also searched for unpublished or ongoing studies on ClinicalTrials.gov, the EU Clinical Trials Register, and the Australian and Ne …
A systematic review of cannabidiol trials in neurodevelopmental disorders.
Parrella NF, Hill AT, Enticott PG, Barhoun P, Bower IS, Ford TC. Parrella NF, et al. Pharmacol Biochem Behav. 2023 Sep;230:173607. doi: 10.1016/j.pbb.2023.173607. Epub 2023 Aug 4. Pharmacol Biochem Behav. 2023. PMID: 37543051 Free article. Review.
However, its suitability as a pharmaceutical intervention has not been reliably established in these clinical populations. This systematic review examines the nine published randomised controlled trials (RCTs) that have probed the safety and efficacy of CBD in indiv …
However, its suitability as a pharmaceutical intervention has not been reliably established in these clinical populations. This syste …
Use of Nutritional Supplements Based on L-Theanine and Vitamin B6 in Children with Tourette Syndrome, with Anxiety Disorders: A Pilot Study.
Rizzo R, Prato A, Scerbo M, Saia F, Barone R, Curatolo P. Rizzo R, et al. Nutrients. 2022 Feb 18;14(4):852. doi: 10.3390/nu14040852. Nutrients. 2022. PMID: 35215501 Free PMC article. Clinical Trial.
BACKGROUND: Tourette syndrome (TS) is a neurodevelopmental disorder characterized by tics and co-occurring disorders. ...Patients affected by Tourette syndrome were randomized to receive nutritional supplements based on L-Theanine and vitamin B6 …
BACKGROUND: Tourette syndrome (TS) is a neurodevelopmental disorder characterized by tics and co-occurring disorders. ...Patie …
Tourette's syndrome.
Müller-Vahl KR. Müller-Vahl KR. Curr Top Behav Neurosci. 2009;1:397-410. doi: 10.1007/978-3-540-88955-7_17. Curr Top Behav Neurosci. 2009. PMID: 21104394
While most patients report beneficial effects when smoking marijuana (Cannabis sativa L.), available clinical trials have been performed using oral delta9-tetrahydrocannabinol (THC). ...
While most patients report beneficial effects when smoking marijuana (Cannabis sativa L.), available clinical trials have been perfor …
Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome.
Mosley PE, Webb L, Suraev A, Hingston L, Turnbull T, Foster K, Ballard E, Gomes L, Mohan A, Sachdev PS, Kevin R, Gordon R, Benson M, McGregor IS. Mosley PE, et al. NEJM Evid. 2023 Sep;2(9):EVIDoa2300012. doi: 10.1056/EVIDoa2300012. Epub 2023 Jun 7. NEJM Evid. 2023. PMID: 38320199 Clinical Trial.
Tetrahydrocannabinol and Cannabidiol in Tourette SyndromeThis randomized controlled crossover trial examined the use of oral tetrahydrocannabinol (THC) with cannabidiol (CBD) to reduce tics in patients with severe Tourette syndrome. ...
Tetrahydrocannabinol and Cannabidiol in Tourette SyndromeThis randomized controlled crossover trial examined the use of oral t …
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.
Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, Martino D, Müller-Vahl K, Woods DW, Robinson M, Jarvie E, Roessner V, Oskoui M. Pringsheim T, et al. Neurology. 2019 May 7;92(19):907-915. doi: 10.1212/WNL.0000000000007467. Neurology. 2019. PMID: 31061209 Free PMC article.
METHODS: This project followed the methodologies outlined in the 2011 edition of the American Academy of Neurology's guideline development process manual. We included systematic reviews and randomized controlled trials on the treatment of tics that included at least 20 par …
METHODS: This project followed the methodologies outlined in the 2011 edition of the American Academy of Neurology's guideline development p …
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Farhat LC, Behling E, Landeros-Weisenberger A, Levine JLS, Macul Ferreira de Barros P, Wang Z, Bloch MH. Farhat LC, et al. Lancet Child Adolesc Health. 2023 Feb;7(2):112-126. doi: 10.1016/S2352-4642(22)00316-9. Epub 2022 Dec 14. Lancet Child Adolesc Health. 2023. PMID: 36528030
BACKGROUND: In clinical practice guidelines there is no consensus about the medications that should be initially offered to children and young people with Tourette's syndrome. ...FINDINGS: Of the 12 088 records identified through the database search, 88 records representin …
BACKGROUND: In clinical practice guidelines there is no consensus about the medications that should be initially offered to children …
1,334 results